264 related articles for article (PubMed ID: 29787732)
1. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Pepose JS; Ahuja A; Liu W; Narvekar A; Haque R
Am J Ophthalmol; 2018 Oct; 194():7-15. PubMed ID: 29787732
[TBL] [Abstract][Full Text] [Related]
2. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis.
Pelletier JS; Stewart K; Trattler W; Ritterband DC; Braverman S; Samson CM; Liang B; Capriotti JA
Adv Ther; 2009 Aug; 26(8):776-83. PubMed ID: 19756415
[TBL] [Abstract][Full Text] [Related]
3. A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.
Ta CN; Raizman MB; Gross RD; Joshi S; Mallick S; Wang Y; Segal B
Am J Ophthalmol; 2020 Jul; 215():56-65. PubMed ID: 32222367
[TBL] [Abstract][Full Text] [Related]
4. Success of Masking 5% Povidone-Iodine Treatment: The Reducing Adenoviral Patient Infected Days Study.
Whiteside MM; Shorter ES; Margolis MS; Alvi F; Huecker JB; Than TP; Migneco MK; Harthan JS; Morettin CE; Hartwick ATE; Johnson SD; Perera CD; Gordon MO
Optom Vis Sci; 2021 May; 98(5):469-475. PubMed ID: 33973917
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis.
Pepose JS; Narvekar A; Liu W; Haque R
Clin Ophthalmol; 2019; 13():535-544. PubMed ID: 30962674
[TBL] [Abstract][Full Text] [Related]
6. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study.
Kovalyuk N; Kaiserman I; Mimouni M; Cohen O; Levartovsky S; Sherbany H; Mandelboim M
Acta Ophthalmol; 2017 Dec; 95(8):e686-e692. PubMed ID: 28342227
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children.
Isenberg SJ; Apt L; Valenton M; Del Signore M; Cubillan L; Labrador MA; Chan P; Berman NG
Am J Ophthalmol; 2002 Nov; 134(5):681-8. PubMed ID: 12429243
[TBL] [Abstract][Full Text] [Related]
8. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis.
Clement C; Capriotti JA; Kumar M; Hobden JA; Foster TP; Bhattacharjee PS; Thompson HW; Mahmud R; Liang B; Hill JM
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):339-44. PubMed ID: 20702820
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
10. The effects of povidone iodine (pH 4.2) on patients with adenoviral conjunctivitis.
Yazar H; Yarbag A; Balci M; Teker B; Tanyeri P
J Pak Med Assoc; 2016 Aug; 66(8):968-70. PubMed ID: 27524529
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone/Povidone Eye Drops versus Artificial Tears for Treatment of Presumed Viral Conjunctivitis: A Randomized Clinical Trial.
Pinto RD; Lira RP; Abe RY; Zacchia RS; Felix JP; Pereira AV; Arieta CE; de Castro RS; Bonon SH
Curr Eye Res; 2015 Sep; 40(9):870-7. PubMed ID: 25310347
[TBL] [Abstract][Full Text] [Related]
12. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study.
Shorter E; Whiteside M; Harthan J; Margolis MS; Hartwick AT; Johnson S; Migneco M; Morettin C; Olson CK; Huecker J; Than T; Gordon MO
Ocul Surf; 2019 Oct; 17(4):828-832. PubMed ID: 31401340
[TBL] [Abstract][Full Text] [Related]
14. The Treatment Models for Adenoviral Keratoconjunctivitis in the Childhood Population.
Bekmez S; Eris E
Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1627-1632. PubMed ID: 32643975
[No Abstract] [Full Text] [Related]
15. Povidone iodine for the treatment of adenoviral conjunctivitis.
Dang RM; Watt K; Hui A
Clin Exp Optom; 2021 Apr; 104(3):308-314. PubMed ID: 33689609
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a Single Administration of 5% Povidone-Iodine in the Treatment of Adenoviral Conjunctivitis.
Than T; Morettin CE; Harthan JS; Hartwick ATE; Huecker JB; Johnson SD; Migneco MK; Shorter E; Whiteside M; Olson CK; Alferez CS; van Zyl T; Rodic-Polic B; Storch GA; Gordon MO
Am J Ophthalmol; 2021 Nov; 231():28-38. PubMed ID: 34102153
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Cinal A
Am J Ophthalmol; 2019 Jan; 197():184. PubMed ID: 30389099
[No Abstract] [Full Text] [Related]
18. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for the Treatment of Adenoviral Conjunctivitis.
Ramakrishnan S; Vempati J; Baskaran P
Am J Ophthalmol; 2019 Aug; 204():140. PubMed ID: 31235065
[No Abstract] [Full Text] [Related]
19. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Pepose JS; Ahuja A; Liu W; Narvekar A; Haque R
Am J Ophthalmol; 2019 Sep; 205():197. PubMed ID: 31327463
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
